Manifestation von Morphea bei einer Patientin mit Myasthenia gravis unter Therapie mit Zilucoplan
Open Access
- 5 February 2026
- journal article
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (2) , 249-251
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- S2k‐Leitlinie: Diagnostik und Therapie der zirkumskripten SklerodermieJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2024
- Zilucoplan: A Newly Approved Macrocyclic Peptide for Treatment of Anti-Acetylcholine Receptor Positive Myasthenia GravisDrugs and Drug Candidates, 2024
- Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension studyTherapeutic Advances in Neurological Disorders, 2024
- Zilucoplan: First ApprovalDrugs, 2023
- Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 studyThe Lancet Neurology, 2023
- Morphea: The 2023 updateFrontiers in Medicine, 2023
- Localized sclerodermaDermatologic Therapy, 2012
- Distinct Autoimmune Syndromes in MorpheaArchives of Dermatology, 2009
- Morphoea lesions are associated with aberrant expression of membrane cofactor protein and decay accelerating factor in vascular endotheliumBritish Journal of Dermatology, 1994